EP

Serial Number 90456179
606

Registration Progress

Application Filed
Jan 8, 2021
Under Examination
Apr 26, 2022
Approved for Publication
Mar 1, 2022
Published for Opposition
Mar 1, 2022
Registered

Trademark Image

EP

Basic Information

Serial Number
90456179
Filing Date
January 8, 2021
Published for Opposition
March 1, 2022
Abandonment Date
October 15, 2025
Drawing Code
5

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Oct 15, 2025
Classes
005 042

Rights Holder

Eledon Pharmaceuticals, Inc.

03
Address
19900 MacArthur Blvd., Suite 550
Irvine, CA 92612

Ownership History

Eledon Pharmaceuticals, Inc.

Original Applicant
03
Irvine, CA

Eledon Pharmaceuticals, Inc.

Owner at Publication
03
Irvine, CA

Legal Representation

Attorney
Gregory B. Phillips

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

44 events
Date Code Type Description Documents
Oct 15, 2025 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Oct 15, 2025 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Oct 22, 2024 EX5G S SOU EXTENSION 5 GRANTED Loading...
Oct 22, 2024 EXT5 S SOU EXTENSION 5 FILED Loading...
Oct 22, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 22, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 8, 2024 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Oct 8, 2024 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Oct 8, 2024 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Apr 26, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Apr 25, 2024 EX4G S SOU EXTENSION 4 GRANTED Loading...
Apr 25, 2024 EXT4 S SOU EXTENSION 4 FILED Loading...
Apr 25, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 25, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 23, 2023 EX3G S SOU EXTENSION 3 GRANTED Loading...
Oct 23, 2023 EXT3 S SOU EXTENSION 3 FILED Loading...
Oct 23, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Apr 27, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Apr 25, 2023 EX2G S SOU EXTENSION 2 GRANTED Loading...
Apr 25, 2023 EXT2 S SOU EXTENSION 2 FILED Loading...
Apr 25, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 26, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 24, 2022 EX1G S SOU EXTENSION 1 GRANTED Loading...
Oct 24, 2022 EXT1 S SOU EXTENSION 1 FILED Loading...
Oct 24, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Apr 26, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Mar 1, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Mar 1, 2022 PUBO A PUBLISHED FOR OPPOSITION Loading...
Feb 9, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jan 27, 2022 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
Jan 27, 2022 ALIE A ASSIGNED TO LIE Loading...
Jan 26, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jan 26, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jan 25, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jan 25, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Nov 2, 2021 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Nov 2, 2021 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Nov 2, 2021 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Jul 27, 2021 GPRN O NOTIFICATION OF PRIORITY ACTION E-MAILED Loading...
Jul 27, 2021 GPRA F PRIORITY ACTION E-MAILED Loading...
Jul 27, 2021 CPRA R PRIORITY ACTION WRITTEN Loading...
Jul 16, 2021 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 8, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jan 12, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical products targeting selected biological pathways, namely, for the treatment of autoimmune and neurodegenerative diseases and for use in organ and cellular transplantation
Class 042
Pharmaceutical research and development and medical research and development in the field of autoimmune and neurodegenerative diseases

Additional Information

Design Mark
The mark consists of a blue stylized letter "E" displayed backwards and adjacent to a blue stylized letter "P".
Color Claim
The color blue is claimed as a feature of the mark.
Pseudo Mark
ELEDON PHARMACEUTICALS

Classification

International Classes
005 042